Abstract: This invention features a method for treating a neurodegenerative disease.

Abstract: The present invention provides pharmaceutically acceptable salts having local anesthetic and anti-inflammatory activities. The preferred pharmaceutically acceptable salt is a diclofenac salt of lidocaine. Diclofenac is a non-steroidal anti-inflammatory drug (“NSAID”). Lidocaine is a local anesthetic. Other NSAID (except the salicylic acid derivatives of NSAID) can be used to replace diclofenac and/or other local anesthetics can be used to replace lidocaine. The pharmaceutically acceptable salts are crystalline compounds, which are distinctively different from either the NSAID alone or the local anesthetic alone, as indicated by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), High Performance Liquid Chromatography (HPLC) and Fourier-Transformed Infrared Spectroscopy (FTIR) analyses.

Abstract: The present invention provides two new microorganism strains of Saccharothrix, designated as YS-44442 and YS-45494, a process of producing pravastatin using the strains, and an improved process for isolation of (HMG)-CoA reductase inhibitors.

Abstract: The present invention discloses a novel and improved pharmaceutical salt, nicotinate, of amlodipine having the following formula: The present invention also discloses methods for preparing and using the same.

Abstract: The present invention provides oral pharmaceutical compositions for acetic acid class of non-steroidal anti-inflammatory drug (NSAID), particularly ketorolac. The pharmaceutical composition contains a core, a drug layer (which comprises the drug, a binder, and a disintegrant), a protecting layer, and an enteric coating layer. The oral pharmaceutical compositons are particularly useful for treating patients with moderate to acute pain. The present invention also provides a method for making the pharmaceutical compositions and a method for using the pharmaceutical compositions.

Abstract: The present invention discloses a novel and improved pharmaceutical salt, nicotinate, of amlodipine having the following formula: 1

Abstract: Methods of treating a disorder associated with low cGMP levels. The methods include administering to a subject in need thereof an effective amount of a compound having a pyrazolyl core, a first aryl group bonded to 3-C of the pyrazolyl core, and a second aryl group fused at 4-C and 5-C of the pyrazolyl core. Also disclosed are pharmaceutical compositions containing these compounds.

Abstract: The present invention provides two new microorganism strains of Saccharothrix, designated as YS-44442 and YS-45494, a process of producing pravastatin using the strains, and an improved process for isolation of (HMG)-CoA reductase inhibitors.

Abstract: The present invention provides a stable pharmaceutical composition which contains an acetic acid class of non-steroidal anti-inflammatory drug (NSAID), a phosphate solution, an isotonic agent, and water. The pharmaceutical composition is particularly suitable for parenteral injection such as intravenous or intramuscular injection. The preferred NSAID is ketorolac tromethamine, which includes any racemic mixture of [−]S and [+]R ketorolac tromethamine. The preferred phosphate solution contains sodium phosphate monobasic (NaH2PO4) or potassium phosphate monobasic (KH2PO4), with or without crystalline water. The preferred isotonic agent is NaCl. The pharmaceutical composition is preferably at pH 6.0 to 8.5 and with osmolarity within 0.5 to 3.

Abstract: A method for treating an angiogenesis-related disorder.

Abstract: The present invention features a method for treating sepsis.

Abstract: Compounds according to formula I: C′—L—T (I), wherein C′ is a camptothecin group; L is a linking moiety; T is a taxoid group, pharmaceutically acceptable salt thereof. The compounds are useful in, among other things, treating cancer in subjects in need thereof, including cellular differentiation, and inhibiting cellular mitosis.

Abstract: Fused tri-heterocyclic compounds of formula: 1

Abstract: The present invention provides a method for making 5-aryloxymethyl-2-oxazolidinone and derivatives thereof having the general formula of: wherein R1 and R2 are hydrogen, alkyl, or alkoxyl group and wherein the alkyl or alkoxyl group contains no more than three carbon atoms in straight or branched chain. The invention involves the fusion of a triglycidyl isocyanurate (TGIC) with an unsubstituted or a mono- or di-substituted phenol.

Abstract: A fused pyrazolyl compound of the following formula: wherein each of Ar1, Ar2, and Ar3, independently, is phenyl, thienyl, pyrrolyl, or furyl, optionally substituted with halo, alkyl, carboxyl, alkoxycarbonyl, thiocarbonyl, aminocarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, or thioalkyl; each of X and Y, independently, is O, S, or NH; m is 1, 2, or 3; and n is 0, 1, 2, 3, or 4. Also disclosed is a pharmaceutical composition containing a pharmaceutically effective amount of the compound described above.

Abstract: A fused pyrazolyl compound of the following formula: 1

Abstract: The present invention provides an herbal composition for improving blood circulation and treating patients with coronary heart diseases and stroke. The herbal composition comprises 30-50 wt % of Dang Gui root (Radix Angelicae sinensis), 35-65 wt % of Chuan Xiong root (Radix Ligustici Chuanxiong), and 7-13 wt % of Ginseng root (Radix Ginseng). The present invention also provides methods of preparing the same.

Abstract: A blank tablet of this invention, typically, includes an absorbent, a disintegrant, a lubricant, and a diluent or a binder, or a mixture of a diluent and a binder. An active ingredient in liquid form is introduced into the blank tablet to produce a pharmaceutical composition.

Abstract: A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.

Abstract: A method of treating a disorder related to cell activation induced by protease-activated receptors. The method includes administering to a subject in need thereof a compound having a pyrazolyl core; an aryl group, via an via an alkylene linker, bonded to 1-N of the pyrazolyl core; a second aryl group fused at 4-C and 5-C of the pyrazolyl core; and a third aryl group bonded directly to 3-C of the pyrazolyl core.